In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 657 for your search:

Drug:  paclitaxel
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML18527, NCT00121836

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 97-02-12, NCT00686322

Phase II/III Randomized Trial of DOX vs TAX vs DOX/TAX/G-CSF in Patients with Metastatic Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: E-1193, NCCTG-923252, SWOG-9332, E-10292, E1193

Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: NBCG10, REK 378-04-03133, NMA 03-07568, NCT00201435

A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA139-384, NCT00337532

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 40 to 75
Sponsor: Other
Protocol IDs: Hamamatsu 18-66, NCT00752115

Paclitaxel and Carboplatin With or Without BMS-275291 in Treating Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: BR18, CAN-NCIC-BR18, BMS-CA161-003, CDR0000068153, NCT00006229

Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: BR24, CAN-NCIC-BR24, ZENECA-CAN-NCIC-BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B, CDR0000450850, NCT00245154

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068744, E4599, CALGB-E4599, ECOG-4599, NCT00021060

10.

Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL/09/105, Funder reference (academic), Funder reference (industry), 2009-017171-13, NCT01196741

11.

An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-001346-41, ISRCTN68510403, NCT00532194

12.

Phase III Randomized Study of Paclitaxel and Carboplatin or Cisplatin Followed By Radiotherapy With or Without Concurrent Paclitaxel in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: INRC-PITCAP, EU-20202, INRC-ITA, NCI-V01-1665, NCT00039039

13.

Phase III Randomized Study of Paclitaxel With or Without Carboplatin as First-Line Chemotherapy in Women With Metastatic Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: THERADEX-B00-1370, BMS-TAX/MEN.13, NCT00025688

14.

Phase III Randomized Study of Carboplatin and Paclitaxel With or Without Erlotinib (Tarceva) in Patients With Chemotherapy Naive Stage IIIB or IV Non-Small Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENENTECH-OSI2298g, MSKCC-01122, NCT00029016

15.

Phase III Randomized Study of Androgen Blockade With Concurrent Chemotherapy Versus Delayed Chemotherapy in Patients With High-Risk Hormone-Naive Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-P-0014, RTOG-DEV-1028, ECOG-RTOG-P-0014, CALGB-RTOG-P-0014, SWOG-RTOG-P-0014, NCT00030654

16.

Phase III Randomized Study of Carboplatin and Paclitaxel With Bexarotene Versus Carboplatin and Paclitaxel Alone in Patients With Chemotherapy-Naive Stage IIIB or IV Non-Small Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-48, BMC-C-7093-49, UCLA-0301086

17.

Phase III Randomized Study of Adjuvant Paclitaxel, Epirubicin, and Cyclophosphamide With or Without Gemcitabine in Women With Completely Resected Early Stage Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CRC-TU-TANGO, EU-20058, NCT00039546

18.

Phase III Randomized Study of Adjuvant Cyclophosphamide and Doxorubicin Versus Single-Agent Paclitaxel in Women With Operable Breast Cancer and 0-3 Positive Axillary Lymph Nodes

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-40101, NCT00041119

19.

Phase III Comparison of CACP/CTX vs CACP/TAX in Patients with Suboptimal Stage III and Stage IV Epithelial Ovarian Carcinoma

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-111

20.

Phase III Randomized Study of High-Dose vs Low-Dose and Long vs Short Infusion Taxol in Patients with Ovarian Cancer Previously Treated with Cisplatin or Carboplatin (Summary Last Modified 12/91)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor:
Protocol IDs: CAN-NCIC-OV9, NCI-V91-0148, OV9

21.

Phase III Randomized Study of CDDP vs TAX vs CDDP/TAX in Patients with Suboptimal Stage III/IV Ovarian Epithelial Carcinoma

Phase: Phase III
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: GOG-132, GOG-0132

22.

Phase III Randomized Trial of Intravenous CDDP/CTX vs Intravenous CDDP/TAX vs Intravenous High-Dose CBDCA Followed by Intravenous TAX/Intraperitoneal CDDP in Patients with Optimal Stage III Ovarian Epithelial Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: GOG-0114, EST-GO114, SWOG-9227

23.

Phase III Randomized Trial of Paclitaxel (Taxol) at 2 Dose Levels and G-CSF at 2 Dose Levels in Patients with Ovarian Carcinoma Previously Treated with Platinum (Summary Last Modified 09/94)

Phase: Phase III
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: GOG-134, E-GO134, NCCTG-926151, SWOG-9238, INT-0134, G0134

24.

Phase III Randomized Study of GM-CSF vs PIXY321 in Patients with Advanced Breast Cancer Receiving FLAC (5-FU/CF/DOX/CTX) Followed by 5 Courses of Continuous-Infusion TAX without Growth Factors (Summary Last Modified 05/94)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-93-C-0153I, NCI-MB-318, NCI-T93-0041N, T93-0041

25.

Phase III Randomized Study of VP-16/CDDP vs TAX/CDDP vs TAX/CDDP/G-CSF in Metastatic and Newly Diagnosed Stage IIIB Nonsmall Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: E-5592, E5592

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map

Other Versions of this Site: Mobile | Español

Follow Us:

Twitter
YouTube
Facebook
RSS

NIH…Turning Discovery Into Health^®